Close

Adverum Biotechnologies (ADVM) Reports L-T Preclinical Efficacy Data on ADVM-022 Gene Therapy in Wet AMD

May 1, 2018 9:08 AM EDT Send to a Friend
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login